Mission Bio Pharma Assay Development Services for Solid Tumor Research

Mission Bio has launched services for solid tumor assays through its Pharma Assay Development business. The services use the firm's Tapestri platform and single-cell solid tumor solution to provide high-resolution data on genetic diversity across cell populations and insights into the clonal landscape and co-occurrence of mutations. Mission Bio said that it offers pharma partners access to a dedicated team to develop assays, identify high-impact samples, and analyze data.